HUMACYTE INC

HUMACYTE insider buying shows top execs bullish on its bio‑engineered skin grafts, even as the stock slides; explore short‑term momentum vs. long‑term regulatory upside.

Keith Anthony Jones’s 30,000‑share purchase of Humacyte at $0.59 shows insider confidence amid volatility, hinting at a short‑term rally but flagging upcoming dilutive options.

Insiders buy 80,000 options each as HUMACYTE’s IPO rolls out, signaling confidence amid volatile pricing and a push to fund Symvess® launches.